Switch theme
Sign up to access all valuation multiples
Jointown Pharmaceutical Group Co Ltd is engaged in the business of wholesaling drugs and medical devices. The company offers logistics and other value-added services and primarily serves medical institutions, wholesale enterprises, and retail pharmacies.
1999
n/a
LTM Revenue $21.8B
LTM EBITDA $659M
$3.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jointown Pharmaceutical has a last 12-month revenue (LTM) of $21.8B and a last 12-month EBITDA of $659M.
In the most recent fiscal year, Jointown Pharmaceutical achieved revenue of $21.1B and an EBITDA of $802M.
Jointown Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jointown Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $21.8B | XXX | $21.1B | XXX | XXX | XXX |
| Gross Profit | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| Gross Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA | $659M | XXX | $802M | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | 4% | XXX | XXX | XXX |
| EBIT | $534M | XXX | $585M | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $342M | XXX | $348M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Jointown Pharmaceutical's stock price is CNY 5 (or $1).
Jointown Pharmaceutical has current market cap of CNY 26.2B (or $3.6B), and EV of CNY 27.0B (or $3.7B).
See Jointown Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.7B | $3.6B | XXX | XXX | XXX | XXX | $0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Jointown Pharmaceutical has market cap of $3.6B and EV of $3.7B.
Jointown Pharmaceutical's trades at 0.2x EV/Revenue multiple, and 4.7x EV/EBITDA.
Equity research analysts estimate Jointown Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jointown Pharmaceutical has a P/E ratio of 10.6x.
See valuation multiples for Jointown Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.6B | XXX | $3.6B | XXX | XXX | XXX |
| EV (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | 5.7x | XXX | 4.7x | XXX | XXX | XXX |
| EV/EBIT | 7.0x | XXX | 6.4x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 10.6x | XXX | 10.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 12.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJointown Pharmaceutical's last 12 month revenue growth is 8%
Jointown Pharmaceutical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Jointown Pharmaceutical's rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jointown Pharmaceutical's rule of X is 22% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jointown Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | -3% | XXX | XXX | XXX |
| Rule of 40 | 11% | XXX | 11% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 22% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jointown Pharmaceutical acquired XXX companies to date.
Last acquisition by Jointown Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Jointown Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Jointown Pharmaceutical founded? | Jointown Pharmaceutical was founded in 1999. |
| Where is Jointown Pharmaceutical headquartered? | Jointown Pharmaceutical is headquartered in China. |
| Is Jointown Pharmaceutical publicy listed? | Yes, Jointown Pharmaceutical is a public company listed on SHG. |
| What is the stock symbol of Jointown Pharmaceutical? | Jointown Pharmaceutical trades under 600998 ticker. |
| When did Jointown Pharmaceutical go public? | Jointown Pharmaceutical went public in 2010. |
| Who are competitors of Jointown Pharmaceutical? | Similar companies to Jointown Pharmaceutical include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of Jointown Pharmaceutical? | Jointown Pharmaceutical's current market cap is $3.6B |
| What is the current revenue of Jointown Pharmaceutical? | Jointown Pharmaceutical's last 12 months revenue is $21.8B. |
| What is the current revenue growth of Jointown Pharmaceutical? | Jointown Pharmaceutical revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Jointown Pharmaceutical? | Current revenue multiple of Jointown Pharmaceutical is 0.2x. |
| Is Jointown Pharmaceutical profitable? | Yes, Jointown Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jointown Pharmaceutical? | Jointown Pharmaceutical's last 12 months EBITDA is $659M. |
| What is Jointown Pharmaceutical's EBITDA margin? | Jointown Pharmaceutical's last 12 months EBITDA margin is 3%. |
| What is the current EV/EBITDA multiple of Jointown Pharmaceutical? | Current EBITDA multiple of Jointown Pharmaceutical is 5.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
